Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease

摘要 这项申请的父母拨款支持CMS121的I期临床试验，CMS121是一种小分子， 在多种阿尔茨海默病小鼠模型中显示出有效性，并提供了一种不同的 治疗人类阿尔茨海默病的方法。在本申请中，我们请求补充资金以 支付新冠肺炎缓解程序和试验对象新冠肺炎测试的费用。这些 在申请时，流程和相关费用并不是必需的，主要是因为 高效疫苗的推出和感染的下降，但由于反复接种，现在变得至关重要 感染激增，出现高传染性的病毒变种。缓解和 测试程序是必要的，以保护临床和非临床人员以及 临床站点来源于新冠肺炎感染。

Abstract The parent grant for this application supports a Phase I clinical trial of CMS121, a small molecule that has shown efficacy in multiple mouse models of Alzheimer's Disease and which affords a different therapeutic approach for treatment of AD in humans. In this application we request supplemental funds to cover the costs of COVID-19 mitigation procedures and COVID-19 testing of trial subjects. These processes and associated costs were not necessary at the time of application due in large part to the rollout of highly effective vaccines and declining infections but have become essential now due to repeated surges in infections and the appearance of highly infectious variants of the virus. The mitigation and testing procedures are necessary to protect the clinical and non-clinical staff, as well as trial subjects at the clinical site from COVID-19 infection.